lets are anti-T.B. formula!ions. Walerburj's Compound (Red Label) h?s been treated as Category IV formulation. Other details as asked for have already been furnished in reply to Rajya Sabha Unstarred Question No. 189 answered on 18th November, 1985. .

Price of Protinex

1536. SHRIMATl MONIKA DAS: Will the Minister of INDUSTRY be pleased to state-.

(a> what is the price fixed for each pack of protinex and whether it is a fact that the prices have not been implemented so far;

(b) if so, what are the reasons therefor;

(c) whether it is a fact that it has been established that Pfizer do not have any Industrial Licence to produce Protinex;

(d) if so, what action has been taken against the company for unauthorised production;

(e) what was the production and sales turn over of Protinex during the laat three years, year-wise;

(f) whether it is a fact that this company is overproducing vitamin products and underproducing essential drugs and formulations; and

(g> if so, what was the production of Vitamins, Tonics, Protein preparations as well as essential products falling under category I and II of DPCO, 1979 during the last three years year-wise?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) Price fixed for Protinex 150 gm. tin and 225 gm- tin inclusive of Excise duty under Drugs (Prices Control) Order, 1979 is Rs. 10.56 and Rs. 17.07 respectively. M/s. Pfizer Ltd. have submitted a representation under Para 27 of the Drugs (Prices Control) Order, 1979 and have not complied with the Government fixed price.

(c> and (d) An Inter Ministerial Committee which was set up in September, 1983 to go into this Question has since submitted its report. The committee has concluded that M/s. Pfizer were licensed to manufacture only bulk drug Proteine Hydrolysate and while they were producing this item, they have been manufacturing Proteinex without any industrial licence for it under the Industries (Development and Regulation) Act, 1951. Further action *on* the findings of the Committee is on.

(e) Information would be collected and laid on the table of the House.

(f) and (g) Companies tailor their production according to demand. Production of formulations is not monitored. However, this company complies with the ratio parametres prescribed under DPCO, 1979.

Unintended benefit on Refampicin

1537. SHRIMATI MONIKA DAS:' Will the Minister of INDUSTRY be pleased to refer the answer to Unstarred Question 121 given in the Rajya Sabha on the 21st January, 1985 and state:

(a) what are the names of tha drug companies whose records have been verified for working out the intended benefit made on Refampicin alongwith amount to be recovered from each;

(bi what is the amount so far recovered from each;

(c) whether it is a fact that crores of rupees have been made by formulators on this Anti-TB and Anti-Leprosy drug when Government exempted the custom and excise duty in order to make it available at cheap price;